Spero Therapeutics (NASDAQ:SPRO) just reported results for the second quarter of 2024.
- Spero Therapeutics reported earnings per share of -33 cents. This was above the analyst estimate for EPS of -38 cents.
- The company reported revenue of $10.20 million.
- This was 211.83% better than the analyst estimate for revenue of $3.27 million.